Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, is a clinical professor at Temple University (TU) School of Pharmacy and a clinical pharmacy specialist in infectious diseases at Temple University Hospital in Philadelphia, Pennsylvania. He also is director of the PGY2 Residency in Infectious Diseases Pharmacy at TU.

Articles by Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Learning the Wrong Lessons

ByJason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

June 15th 2021

Let’s Say It Out Loud: Being Vaccinated Has Benefits

ByJason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

April 13th 2021

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

COVID-19: Grading the Year in Review

ByJason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

February 9th 2021

Our editor-in-chief rates the first year of response to the pandemic.

Emergency Use Authorizations for COVID-19 Therapeutics: The Good, the Bad, and the Data-Deficient

ByJason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

December 19th 2020

COVID-19 Vaccination: Prepare to Engage

ByJason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

October 13th 2020

Imipenem-Cilastatin-Relebactam: Imipenem Is Rele Back Again

ByToni Campanella, PharmD*,Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

February 13th 2020

The US Food and Drug Administration approved imipenem-cilastatin-relebactam to treat complicated intra-abdominal infections and complicated urinary tract infections in adults with limited treatment options.